Drugs / CAR.CD30 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01316146 | Oct 2011 → Jan 2016 | Hodgkins lymphoma, non-Hodgkin lymphoma | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR.CD30 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01316146 ↗ |
| Known as | CD30.CAR-Ts | “9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR...” PMID 28805662 ↗ Aug 2017 |
| Action | Deplete | “Investigators now want to see if they can attach a gene to T cells that will help them do a better job at recognizing and killing lymphoma cells.” NCT01316146 ↗ |
| Modality | Cell therapy | “autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts)” PMID 28805662 ↗ Aug 2017 |
| Route | Intravenous | “CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.” NCT01316146 ↗ |